Literature DB >> 23820763

Determining the appropriate time of execution of an I-131 post-therapy whole-body scan: comparison between early and late imaging.

Massimo Salvatori1, Germano Perotti, Maria F Villani, Rocco Mazza, Maria L Maussier, Luca Indovina, Alessandro Sigismondi, Massimo E Dottorini, Alessandro Giordano.   

Abstract

OBJECTIVE: The aim of this study was to investigate the appropriate time for performing an iodine-131 post-therapy whole-body scan (TxWBS) through a qualitative and semiquantitative analysis of early and late scans.
MATERIALS AND METHODS: This study evaluated pairs of scans of 134 patients who underwent TxWBS on the third and seventh day. The scans were analyzed to evaluate sites, intensity of uptake, concordance or discordance between the scans, relationship with risk factors, and serum thyroglobulin (Tg) levels. To evaluate early and late radioiodine kinetics in thyroid remnants and metastases, 65/134 pairs of scans (48.5%) were subjected to a semiquantitative analysis.
RESULTS: The early and late scans furnished concordant images in 108/134 patients (80.5%). In 10/134 patients (7.5%), early scans provided more information compared with late scans, showing lymph node and distant metastases in seven and three patients, respectively. In 16/134 patients (12%), late scans provided more data compared with early scans, with thyroid remnants and lymph node and distant metastases demonstrated in four, seven, and five patients, respectively. Negative early/positive late TxWBS results in patients were found to be significantly correlated (P=0.007) with elevated serum levels of Tg and a high-risk for recurrence (P=0.003).
CONCLUSION: This study suggests that in about 20% of patients early or late TxWBS can miss the visualization of thyroid remnants or lymph node or distant metastases, which can be achieved performing both studies. High-risk patients with elevated serum Tg levels should be considered for a late TxWBS, which can demonstrate a possible metastatic involvement that was not diagnosed or that was downstaged by early TxWBS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23820763     DOI: 10.1097/MNM.0b013e328363cc5c

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

Review 1.  Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.

Authors:  Prasanna Santhanam; Lilja B Solnes; Steven P Rowe
Journal:  Med Oncol       Date:  2017-10-30       Impact factor: 3.064

Review 2.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

3.  Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans?

Authors:  Gauri R Khorjekar; Douglas Van Nostrand; Carlos Garcia; Jeffrey O'Neil; Shari Moreau; Francis B Atkins; Mihriye Mete; Michael H Orquiza; Kenneth Burman; Leonard Wartofsky
Journal:  Thyroid       Date:  2014-06-20       Impact factor: 6.568

Review 4.  Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer.

Authors:  Zhuan-Zhuan Mu; Xin Zhang; Yan-Song Lin
Journal:  Chonnam Med J       Date:  2019-09-24

5.  30 mCi exploratory scan for two-step dosimetric 131I therapy in differentiated thyroid cancer patients: A novel approach and case report.

Authors:  Di Wu; Cristiane Jeyce Gomes-Lima; Kanchan Kulkarni; Kenneth D Burman; Leonard Wartofsky; Douglas Van Nostrand
Journal:  World J Nucl Med       Date:  2020-01-17

6.  A semiquantitative study of the optimal whole-body imaging time after 131I therapy for differentiated thyroid cancer.

Authors:  Shuang Liu; Rui Zuo; Tianyu Yang; Hua Pang; Zhengjie Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-25       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.